88IV - PR Newswire Asia's news - Health Care/Hospital

< Previous page

| Title only | Print

Next page >

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program SAN DIEGO , June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global ... 2026-06-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 HONG KONG , June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific ... 2026-06-08T Health Care/Hospital Medical/Pharmaceuticals
OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma SHANGHAI , June 8, 2026 /PRNewswire/ -- OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , annou nced that its proprietary GPC3-targeted autologous CAR-T therapy, ... 2026-06-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance SHANGHAI and HONG KONG , June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated ... 2026-06-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide NEW ORLEANS , June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing ... 2026-06-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Global Rise in Delayed Childbearing and Infertility Drives Demand for Cross-Border Fertility Care Asian Case Studies Highlight How Regulation, Cost, and Access Are Shaping International Family Choices ... 2026-06-06T Health Care/Hospital Medical Equipment Medical/Pharmaceuticals
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment ... 2026-06-06T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Quantinuum Announces Closing of Upsized Initial Public Offering BROOMFIELD, Colo. , June 6, 2026 /PRNewswire/ -- Quantinuum Inc. (Nasdaq: QNT) ("Quantinuum") today announced the closing of its upsized initial public offering of 28,000,000 shares of its ... 2026-06-06T Computer/Electronics Health Care/Hospital
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP28 1 ... 2026-06-06T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval NANJING, China , June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the ... 2026-06-05T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved